FindTrial
Sign In

To study the effect of a Sunscreen tablet in humans with pigmentation.

To evaluate Efficacy and in use tolerance of Oral Sun Protection Nutraceutical Tablet in Men and Women with Melasma. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/095866
Enrollment
36
Registered
2025-10-10
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: BanRay Oral Sun Protection Nutraceutical Tablet: One Tablet to be taken Once daily after breakfast, orally, to be swallowed with water for a duration of 60 days. Control Intervention1:

Sponsors

Ajanta Pharma Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Voluntary men and or women from 18 years to 55 years of age with mild to moderate melasma will be included. 2. Photo type III to IV. 3. Having otherwise healthy skin on test area. 4. Participants showing abnormal levels in blood test parameters. (Subjects having abnormal values but are Clinically fit to participate in the trial would be enrolled in the study at Principal Investigator s Discretion). 5. Willing to avoid unusual sun exposure as far as possible for the entire study duration. 6. Accepting not to use oral supplement with the same end benefit during the entire study duration. 7. Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures. 8. Ready to provide consent, having been informed orally and in writing of all information concerning the study procedures and study objectives.

Exclusion criteria

Exclusion criteria: 1. Female who is pregnant (UPT)or lactating women. 2. Participants hypersensitive to any of the components of the test product. 3. Participants on any systemic medical treatment which may interfere with the performance of the study treatment (presently or in the past 1 month). 4. Participant in an exclusion period or participating in any clinical trial within 30 days prior to screening.

Design outcomes

Primary

MeasureTime frame
1. 3D Imaging for Skin Tone evenness and hyperpigmentation. 2. Melasma Area Severity Index (MASI Scale) for the assessment of melasma. 3. Self-assessment for product efficacy.Timepoint: Day 0, Day 30, Day 60—

Secondary

MeasureTime frame
Self-assessment questionnaire for in use tolerance.Timepoint: Day 30, Day 60—

Countries

India

Contacts

Public ContactMs Preetha Paul

Clinical Aesthetics and Investigative Management Service Pvt. Ltd. (C.L.A.I.M.S.PVT.LTD.

preetha@claimsclinical.com66758851

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026